Close Menu

NEW YORK (GenomeWeb) – Qiagen said Wednesday after the close of the market that that it has signed an agreement with McKesson Medical-Surgical, an affiliate of McKesson, to serve as the exclusive distributor of the QiaStat-Dx syndromic testing platform in the "acute" market segment of US hospitals with 200 or fewer beds.

The agreement also makes McKesson a non-exclusive distributor for QiaStat-Dx's future expansion into clinics located in US retail pharmacies.

Qiagen said it will continue its sales and marketing efforts in larger hospitals and clinical laboratories.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.